Hemostasis Today

February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
GENB-OAC Study Insights from Gabrielle Sarlon and The Team
Feb 15, 2026, 06:04

GENB-OAC Study Insights from Gabrielle Sarlon and The Team

RPTH Journal shared on LinkedIn:

”New data about abnormal uterine bleeding under oral anticoagulants,

Abnormal uterine bleeding (AUB) is a frequent and underestimated complication in women of reproductive age receiving anticoagulation for venous thromboembolism.

Key findings from the GENB-OAC study (multicenter, national cohort):

AUB was significantly more frequent in women on oral anticoagulants compared with controls

Rates were higher with rivaroxaban and vitamin K antagonists compared with apixaban

Clinically relevant non-major bleeding and heavy menstrual bleeding were more common with rivaroxaban

Quality of life was reduced in women receiving anticoagulation, with no significant difference between oral anticoagulant groups”

Title: Prevalence of abnormal uterine bleeding and quality of life after venous thromboembolism by oral anticoagulant use: the GENB-OAC Study

Authors: Gabrielle Sarlon-Bartoli, Barbara Leclercq, Nathalie Trillot, Isabelle Mahé, Marie Daoud-Elias, Andrea Buchmuller, Geraldine Poenou, Antoine Elias, Jean Noel Poggi, Francis Couturaud, Noemie Resseguier, Martin Postzich, Lylia Hammoudi, Yasmine Benredouane, Florence Bretelle, Louisa Goumidi, Pierre Suchon, Sarah Jidal, Antonia Perez-Martin, Clementine Rousselin, Isabelle Quere, Sandrine Mestre, Marie Antoinette Sevestre, Simon Soudet, Laurent Bertoletti, Sophie Susen, Pierre Emmanuel Morange

Read the Full Article on RPTH Journal/PubMed

GENB-OAC Study Insights from Gabrielle Sarlon and The Team

Stay updated on all scientific advances with Hemostasis Today.